On 5 August 2020, Hepion announced that it had dosed the first NASH patient with CRV431 in its Phase IIa ‘AMBITION’ pilot study. The primary endpoint of AMBITION is to assess the safety and tolerability of CRV431 at a 75mg dose and the company expects data from the trial in Q420. The goal of the study outside the endpoints is to gather a range of different biomarkers in these patients to examine CRV431 for activity, which will be used to support the design of future studies.
07 Aug 2020
Hepion Pharmaceuticals - Phase IIa trial commenced
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hepion Pharmaceuticals - Phase IIa trial commenced
Hepion Pharmaceuticals, Inc. (HEPA:NAS) | 0 0 0.0%
- Published:
07 Aug 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
5
On 5 August 2020, Hepion announced that it had dosed the first NASH patient with CRV431 in its Phase IIa ‘AMBITION’ pilot study. The primary endpoint of AMBITION is to assess the safety and tolerability of CRV431 at a 75mg dose and the company expects data from the trial in Q420. The goal of the study outside the endpoints is to gather a range of different biomarkers in these patients to examine CRV431 for activity, which will be used to support the design of future studies.